This study is testing a treatment to see if it can lower antibodies in people on the kidney transplant waiting list.
Lowering these antibodies may make it easier to match with more donors. The study is also checking how safe the treatment is and whether it helps with successful transplants.
Anticipated date enrolment will close: 31 December 2025
Who can take part
- Adults on the deceased donor kidney transplant waiting list
- Have high levels of antibodies that make matching with donors difficult
- Are not pregnant, breastfeeding, or planning pregnancy
- Cannot take part if recently had live vaccines or certain medications
- Cannot take part if they have certain infections or medical conditions
Other criteria may apply
What is involved for participants
- Regular injections of the study drug every 4 weeks (up to 1 year)
- About 12 to 15 clinic visits over the year
- Blood tests, pregnancy tests, and chest x-ray
- Kidney biopsies before and after transplant (as needed)
- Continued treatment if transplant occurs during the study
- Possible use of antibiotics and other medicines to support treatment
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.